This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag: Elan

Moving on. It was also a great week because Vanda Pharmaceuticals (VNDA - Get Report) received a non-approvable letter for its schizophrenia drug Fanapta -- another prediction of mine in the win column.

The Vanda news prompted Steve P. to write:
"The world, as we know, is coming to an end if a straightforward rational assessment of clinical trial data actually results in a logical, predictable response by the FDA. Congrats -- I am just amazed that there seems to be so much surprise by those who ought to know better."

I couldn't agree more, and I love Steve's snark. There are people out there doing the real work who get stuff like predicting the Food and Drug Administration's takedown of Vanda correct. I'm fortunate to know one of those guys because he makes me look smarter than I am.

Go back to my January column on Vanda. My source, a hedge fund analyst, said that FDA would issue a non-approvable letter based on his analysis of the company's clinical trial data. He nailed it cold.

Lastly, an email from David K., who asks: "Who is the best CEO in the pharmaceutical industry?"

I don't follow Big Pharma all that closely, so I hope David doesn't mind if I tweak his question towards biotech CEOs.

Genentech's (DNA) Art Levinson has to be in the top tier, as does Gilead Sciences' (GILD - Get Report) John Martin. Myriad Genetics (MYGN - Get Report) isn't a pure biotech, but the way CEO Peter Meldrum managed to get $100 million from Lundbeck for a failed Alzheimer's drug that actually pushed his stock higher puts him in the genius category. BioMarin's (BMRN - Get Report) J.J. Bienaime has done a marvelous job turning around that company into one of the best-performing mid-cap stocks in the sector.

This isn't an exhaustive list, so let me turn the question around to all of you. Send me your pick for the best CEO in biotech. At the end of the year, I'll pick a winner and we'll celebrate his (or her) greatness right here.

And remember, I'm still seeking nominations for worst biotech CEO of the year. Elan's Martin appears to be making a strong run now, but who else do you think deserves the ignominy?

In the coming weeks, be on the lookout for a brand new product from Adam Feuerstein and! Should you wish to hear more about this special invitation and how you can take advantage of some exciting pre-launch offers please email.

Has the stock market bottomed?

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
BIIB $263.86 0.00%
BMRN $68.41 0.00%
GILD $85.14 0.00%
MYGN $36.12 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs